Rydapt (midostaurin) — CareFirst (Caremark)
Systemic mastocytosis with associated hematological neoplasm (SM-AHN)
Initial criteria
- Rydapt is used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months